Atlas market file · Equity · United States
Dr Reddys Laboratories LtdRDY
- Last close
- 12.22
- Change
- +0.91%
- 96-bar range
- 11.36 – 15.67
- As of
- 7 Aug 2026
Dr Reddys Laboratories Ltd is a pharmaceutical preparations issuer listed as RDY on NYSE. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
RDY
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-25.63% over the window).
Source rail: Yahoo Finance chart API (RDY). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for RDY. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
Atlas Pro artifact
RDY Market Snapshot PDF
The latest snapshot audit passed. Atlas checks entitlement and evidence again when the PDF is requested.
Atlas Pro entitlement required. The release gate runs again when you request the file.
RDY public profile
Pharmaceutical preparations issuer. Dr Reddys Laboratories Ltd is connected to current market context, cited company sources and its retained research file.
Dr Reddys Laboratories Ltd trades as RDY on NYSE. Dr Reddys Laboratories Ltd (RDY) has a latest verified close of 12.22, up 0.91%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files RDY under USA Stocks for browsing.
What changed for Dr Reddys Laboratories Ltd today
RDY’s strongest supplied development is Obeda: Dr Reddy’s Laboratories says it has launched a generic semaglutide injection for Type 2 diabetes and says it is the first Indian company to receive DCGI approval for this GLP-1 receptor agonist. That gives the daily file a concrete medicines story, not just a corporate slogan.
The company’s official rail presents Dr Reddy’s as a pharmaceutical business built around access, active pharmaceutical ingredients, healthcare professional programmes and broader business capabilities. The repeated line across the source set is “Accelerating access to affordable and innovative medicines”, which matters because the supplied evidence keeps pulling the equity back to products, supply and healthcare delivery rather than abstract market language.
The filing and earnings rail is thin. The supplied packet does not provide revenue, profit, EPS, cash flow, capital ratios, dividend, buyback, guidance or segment figures. The one operational figure supplied is from the official source page: cost improvement projects and stronger site-level waste checks delivered a 20-22% reduction in waste across 9 high-volume products.
The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. The market mechanism available from the evidence is the operating one: a named GLP-1 product launch, an official API and services rail, healthcare professional programmes, stated capabilities and a waste-reduction claim tied to high-volume products.
What changed in this packet is the prominence of a named product and regulatory claim: Obeda, generic semaglutide injection, Type 2 diabetes, DCGI approval. What remains unproven is the commercial weight of that development. The evidence does not show sales, margin, capacity, doctor uptake or patient access data.
A deeper RDY file would need parsed earnings and filing facts: revenue, profit, EPS, cash flow, guidance, segment performance and any quantified contribution from Obeda or the 20-22% waste reduction. Until then, the evidence supports a precise product-and-operations story, not a full financial verdict.
Sources & evidence · 5 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
RDY technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on RDY
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep RDY research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
RDY FAQ
What is Dr Reddys Laboratories Ltd (RDY)?Dr Reddys Laboratories Ltd (RDY) has a latest verified close of 12.22, up 0.91%, dated 7 Aug 2026. Use this page to check the price chart, company context,...
Dr Reddys Laboratories Ltd (RDY) has a latest verified close of 12.22, up 0.91%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for RDY?Dr Reddys Laboratories Ltd (RDY) has a latest verified close of 12.22, up 0.91%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources,...
Dr Reddys Laboratories Ltd (RDY) has a latest verified close of 12.22, up 0.91%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files RDY under USA Stocks for browsing.
How often is the RDY page updated?The RDY public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The RDY public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for RDY?The RDY file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NYSE:RDY. SEC EDGAR provides the filing anchor for this issuer. The page separates verified...
The RDY file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NYSE:RDY. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on RDY?Yes. The workstation can open RDY, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open RDY, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this RDY page investment advice?No. The RDY page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The RDY page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →